Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT05335356 is registered in ClinicalTrials.gov with Biocon Biologics UK Ltd as lead sponsor.

NCT NCT05335356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05335356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
Lead sponsor
Biocon Biologics UK Ltd
Phase
Phase 3
Overall status
Completed
Start date
June 28, 2022
Completion date
November 15, 2023
Enrollment
384 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe chronic plaque psoriasis